 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12...1213141516171819202122...4950» |
- | New trial: Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study (clinicaltrials.gov) - Nov 21, 2021
P=N/A, N=20, Recruiting, Sponsor: Institut de cancérologie Strasbourg Europe
- ||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Clinical, Journal, Adverse events: Comparison of Adverse Events during EC or TC Therapy for Breast Cancer at the Kakogawa Central City Hospital (Pubmed Central) - Nov 21, 2021
Docetaxel and cyclophosphamide (TC) and epirubicin and cyclophosphamide (EC) therapies are postoperative chemotherapy regimens for breast cancer...We observed no significant differences in the dose-reduction/discontinuation of chemotherapy or admission. However, in the TC therapy group, 5 patients required admission.
- | Avastin (bevacizumab) / Roche
Journal: Microsphere TACE with Arterial Infusion of Bevacizumab for Portal Vein Tumor Thrombus by Hepatocellular Carcinoma (Pubmed Central) - Nov 21, 2021
Bevacizumab, anti-VGEF monoclonal antibody, was injected into hepatic arteries with anti-neoplastic agents, followed by the epirubicin-loaded superabsorbent polymer microsphere( HepaSphere). The tumor thrombi in 2 cases were successfully eliminated after treatment for more than 2 years without deterioration of the hepatic function.
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Biomarker, Clinical, Journal: Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer. (Pubmed Central) - Nov 17, 2021
In Kaplan-Meier estimates of ER+ patients divided by the median of the post/pre-treatment sTK1 ratio at the first treatment cycle, OS was 97.7% and 78% (p = 0.005), and DFS was 90.7% and 68% (p = 0.006), respectively. Thus, the response of sTK1 at the first cycle of chemotherapy could be used both as an early biomarker for the guidance of chemotherapy and for the study of inherent tumor chemo-sensitivity, which could predict long-term outcome prior to therapy.
- | Vumon (teniposide) / BMS
Journal: Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer. (Pubmed Central) - Nov 17, 2021
Finally, we observed significant TOP2A copy number gains and increased expression in independent cohorts of rectal cancer patients. These findings can be translated into clinical practice to evaluate TOP2A status for targeted and personalized therapies based on topoisomerase II inhibitors in rectal cancer patients.
- | epirubicin / Generic mfg.
Journal: Drug Loading of Anthracycline Antibiotics on Carbon Dots Using Circular Dichroism Spectrometry. (Pubmed Central) - Nov 17, 2021
Herein, as a feasible pathway to shed light on improving nano drug quantification procedures, we proposed a simple analytical protocol to quantify the anthracyclines loaded on our nonchiral carbon nitride dots (CNDs) with circular dichroism spectrometry (CD). The calibration curves from the linear relation between ellipticity and concentration of the anthracycline drugs followed by measurements on the CNDs conjugates were used in achieving the quantification technique which showed different drug loading for each anthracycline used such as daunorubicin, doxorubicin, and epirubicin.
- || epirubicin / Generic mfg.
Clinical, Clinical data, Retrospective data, Journal: Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes. (Pubmed Central) - Nov 17, 2021
The calibration curves from the linear relation between ellipticity and concentration of the anthracycline drugs followed by measurements on the CNDs conjugates were used in achieving the quantification technique which showed different drug loading for each anthracycline used such as daunorubicin, doxorubicin, and epirubicin. TACE using a GMD is effective and safe in clinical practice.
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion date, Trial primary completion date: ISG-STS-1001: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy (clinicaltrials.gov) - Nov 16, 2021
P3, N=550, Active, not recruiting, Sponsor: Italian Sarcoma Group
TACE using a GMD is effective and safe in clinical practice. Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023
- | epirubicin / Generic mfg.
Journal: Epirubicin and Cyclophosphamide-induced Acute Fibrinous and Organizing Pneumonia. (Pubmed Central) - Nov 16, 2021
Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023 No abstract available
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. (Pubmed Central) - Nov 16, 2021
Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial, Metastases: A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 15, 2021
P3, N=256, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | epirubicin / Generic mfg.
Preclinical, Journal: In Vitro Reconstitution of the dTDP-l-Daunosamine Biosynthetic Pathway Provides Insights into Anthracycline Glycosylation. (Pubmed Central) - Nov 10, 2021
The sugar moiety, l-daunosamine (a highly modified deoxyhexose), plays a key role in the bioactivity of these molecules as evidenced by semisynthetic anthracycline derivatives such as epirubicin, wherein alteration in the configuration of a single stereocenter of the sugar unit generates a chemotherapeutic drug with lower cardiotoxicity...Our in vitro reconstituted pathway also provided a platform to test the combinatorial enzymatic synthesis of other dTDP-activated deoxyhexoses as potential tools for "glycodiversification" of natural products. To this end, we replaced the stereospecific ketoreductase that acts in the last step of dTDP-l-daunosamine biosynthesis with an enzyme from a heterologous pathway with opposite stereospecificity and found that it is active in the in vitro pathway, demonstrating the potential for the enzymatic synthesis of nucleotide-activated sugars with regio- and stereospecific tailoring.
- | epirubicin / Generic mfg.
Journal: Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs). (Pubmed Central) - Nov 10, 2021
Using time-lapse imaging and RNAseq, we found that the differences in anthracycline cardiotoxicity are closely linked to extent of cardiomyocyte uptake and magnitude of activation/inhibition of several cellular pathways such as death receptor signaling, ROS production, and dysregulation of calcium signaling. The results provide molecular insights into anthracycline cardiac interactions and offer a novel assay system to more robustly assess potential cardiotoxicity during drug development.
- Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5251;
Zanubrutinib plus R-CHOP demonstrated promising efficacy as front-line regimen in IVLBCL, even in the CNS involvement patients. This regimen is well tolerated and it warrants future investigation in larger scale population and long-term follow-up.
- The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4113;
P2
The BCHEP regimen may serve as a novel first-line treatment option for patients with PTCL. The study is going on to enroll patients and updating results, including the prognostic value of serum inflammatory factors.
- || epirubicin / Generic mfg.
Clinical, Journal: Clinical Characteristics of Transarterial Chemoembolization in Treatment of Primary Hepatocellular Carcinoma Complicated With Respiratory Distress Syndrome. (Pubmed Central) - Nov 5, 2021
In this study, we found that although the incidence of ARDS after TACE was low in the treatment for HCC, the symptoms after onset were serious, and the early hormone therapy may be beneficial to improve the prognosis and reduce mortality. Further research with larger samples is still needed to confirm the pathogenesis of ARDS after TACE in the treatment for HCC.
- | epirubicin / Generic mfg.
Journal: Preferential Binding of Epirubicin Hydrochloride with Single Nucleotide Mismatched DNA and Subsequent Sequestration by a Mixed Micelle. (Pubmed Central) - Nov 5, 2021
Additionally, we have shown that EPR can be sequestered from nucleic acids using a mixed micellar system of an anionic surfactant and a triblock copolymer. From thermal denaturation studies and circular dichroism spectroscopy, we found that the extent of drug sequestration depends on the binding affinity of EPR to the duplex DNA, and this mixed micellar system can be employed for the removal of excess drug in the case of a drug overdose.
- | paclitaxel / Generic mfg., epirubicin / Generic mfg.
Journal: Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment. (Pubmed Central) - Nov 4, 2021
Furthermore, vimentin overexpression alone rendered the native cells resistant to the drugs, while vimentin knockdown rendered them more sensitive to the drugs. Together, our data suggest that vimentin could be considered as a new targetable player in the ever-elusive status of drug resistance and recurrence of TNBC.
- || tamoxifen / Generic mfg., methotrexate / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy. (Pubmed Central) - Nov 2, 2021
IGKC expression had an independent prognostic impact in early breast cancer patients who received adjuvant chemotherapy. There was a significant interaction with the use of tamoxifen.
- || Avastin (bevacizumab) / Roche
Biomarker, Clinical, Journal: Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer. (Pubmed Central) - Oct 31, 2021
Serial measurement of serum TK1 activity during neoadjuvant chemotherapy provides long-term prognostic information in BC patients. The ease of obtaining serial samples for TK1 assessment motivates further evaluation in larger studies.
- | CBT-1 (tetrandrine) / CBA Pharma
Journal: Enhanced antitumor efficiency of RGD modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumor metastasis. (Pubmed Central) - Oct 30, 2021
In vivo results exhibited that RGD modified epirubicin plus tetrandrine liposomes could enhance the accumulation in tumor site and display an obvious antitumor efficiency. Therefore, RGD modified epirubicin plus tetrandrine liposomes could be used as a potential therapy for treatment of gastric cancer.
- || epirubicin / Generic mfg.
Clinical, Journal: The morphological changes of the colonic goblet cells and mucin profile in oncohematological patients under Epirubicin-based chemotherapy. (Pubmed Central) - Oct 30, 2021
The MUC2 and MUC4 showed a decreased immunoexpression at 48 hours after the Epirubicin administration compared to controls and partially restored three weeks after the cessation. Overall, it is highly plausible that all these key players revolve around the chemotherapy-induced mucositis in oncohematological patients and highlights the morphofunctional particularities of the GCs, which further modulates the clinical outcome of the patient.
- | epirubicin / Generic mfg.
Journal: Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. (Pubmed Central) - Oct 30, 2021
In tumor-bearing mice, EPI-SL significantly improved the tumor-targeting efficiency and therapeutic efficacy of EPI compared to other preparations and even eradicated tumors because of the tumor-accumulating and inhibitory effects of N/Ms containing EPI-SL. Our research showed, for the first time, that as an N/M-based drug delivery platform, EPI-SL remedied the limited tumor targeting in the conventional EPR effect-based treatment strategy, contributing to the exploitation of a new drug delivery platform for cancer treatment.
- | Yinuokai (orelabrutinib) / InnoCare, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 28, 2021
P3, N=100, Recruiting, Sponsor: Shandong Provincial Hospital
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: EXELOX: The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Oct 26, 2021
P3, N=438, Completed, Sponsor: Fudan University
Our research showed, for the first time, that as an N/M-based drug delivery platform, EPI-SL remedied the limited tumor targeting in the conventional EPR effect-based treatment strategy, contributing to the exploitation of a new drug delivery platform for cancer treatment. Recruiting --> Completed | Trial completion date: Mar 2018 --> Feb 2021 | Trial primary completion date: Mar 2017 --> Feb 2021
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
A randomized, multicenter phase III study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting dimeric rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1560;
P3
F-627 provides the Chinese oncologists an alternative for simplifying the management of chemotherapy-induced neutropenia. The study was approved by the National Medical Products Administration of China (registration number: 2017L04033), and was registered on www.chinadrugtrials.org.cn (registration number: CTR20170705) and ClinicalTrials.gov (registration number: NCT04174599).
- Vectibix (panitumumab) / Amgen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Remodeling the inflammatory breast cancer tumor microenvironment to enhance immunotherapy: Novel therapeutic development (Stars at Night 1/2) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1508;
P2
This modulation of the TME by panitumumab improves the inhibition of IBC tumor growth by an ICI. Our study is the first to demonstrate that targeting the EGFR/EGR1 axis remodels the IBC TME by regulating chemokine expression, thus boosting the antitumor immune response in IBC and response to ICI.
- goshajinkigan (TJ-107) / Tsumura, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Compression therapy and goshajinkigan for prevention of nab-paclitaxel-induced peripheral neuropathy in patients with operable breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1463;
Compression therapy with elastic stockings and GJG were effective to prevent PN associated with DD nab-PTX regimen. Preventive approach for PN may improve dose intensity of taxane and long-term QOL of breast cancer patients.
- Herceptin (trastuzumab) / Roche
Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study (Stars at Night 3/4) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1438;
P3
Pyrotinib, trastuzumab, and docetaxel as neoadjuvant treatment achieved a statistically significant and clinically meaningful improvement in IRC-assessed tpCR rate for patients with HER2-positive early or locally ABC compared with placebo, trastuzumab, and docetaxel, with an acceptable and manageable safety profile. These findings support pyrotinib, trastuzumab, and docetaxel as a new neoadjuvant treatment option in this patient population.
- tamoxifen / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Single nucleotide polymorphisms and mortality after docetaxel-based chemotherapy in premenopausal breast cancer: A population-based cohort study in Denmark (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_972;
Conclusions In this study, mortality may be associated with SNPs in ABCB1, ABCC2, SLCO1B1, CYP3A and GSTP1 in premenopausal women with non-metastatic breast cancer receiving docetaxel. The mechanisms underlying our findings remains unclear but may be related to docetaxel pharmacokinetics.
- Herceptin (trastuzumab) / Roche, EG12014 (trastuzumab biosimilar) / EirGenix, Novartis
A phase III, randomized, multicenter, double-blind study to compare efficacy and safety of EG12014 (EirGenix trastuzumab) with Herceptin ® as neoadjuvant treatment in combination with anthracycline/paclitaxel-based systemic therapy in patients with HER2-positive early breast cancer - a multinational phase III study conducted during the COVID-19 pandemic (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_784;
P3
The impact of the COVID-19 pandemic has been comparable between the two treatment arms. The influence of the pandemic on this clinical study has been relatively low considering timing and the participating countries.
- Herceptin (trastuzumab) / Roche
High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_779;
P3
This is the first study to show that high CD36 expression is independently predictive of worse long-term clinical outcomes in HER2+ BC patients treated with neoadjuvant trastuzumab-based therapy. Along with recent preclinical data highlighting CD36 role in tumor resistance to anti-HER2 therapies, our findings point to CD36 as a novel promising target for HER2+ BC treatment.
- docetaxel / Generic mfg., epirubicin / Generic mfg.
Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_766;
We hypothesized that early evaluation of FDG PET after the first course of docetaxel (DTX) would predict treatment resistant group by the relationship between changes on FDG accumulation and tumor diameter on magnetic resonance imaging (MRI)...Four courses of DTX were administered followed by 4 courses of fluorouracil/epirubicin/cyclophosphamide (FEC) followed by surgery...The low SUVmax change group showed shorter PFS than the high SUVmax group (median 80.9 vs 93.7 months, p=.050), but there was no difference in OS (p=.719). [Conclusion] Changes less than 30% of 18F-FDG uptake after the first course of DTX may reflect the treatment resistance and poor prognosis in primary breast cancer.
- Herceptin (trastuzumab) / Roche
Effect of moderate physical exercise on the immune system modulation in breast cancer patients during preoperative chemotherapy: The NEO-RUNNER study (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_759;
Trastuzumab and carboplatin were added in HER2 positive and high-risk triple negative BC pts, respectively...In TR pts MPA may help to restore the immune profile similar to that of HV. At T3, the same percentage of TR and UN pts were close to HV indicating that tumor removal damped the cancer related anti-inflammatory status.
- carboplatin / Generic mfg., epirubicin / Generic mfg.
Efficacy of neoadjuvant systemic carboplatin therapy in triple-negative breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_750;
Even after dose-modification of CBDCA (e.g. for toxicity) it seems to be effective compared to discontinuation or no inclusion of CBDCA. Our data support the current recommendations to include CBDCA in neoadjuvant therapy for TNBC.
- Herceptin (trastuzumab) / Roche
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: Final long-term results of the hellenic cooperative oncology group phase III HE10/05 trial (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_523;
Overall, no significant differences in DFS or OS were found amongst the studied regimens after a long-term observational period. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000151033
- || epirubicin / Generic mfg.
Clinical, Preclinical, Journal: Intraarterial Lidocaine Administration for Pain Control by Water-in-Oil Technique in Transarterial Chemoembolization: in vivo and Randomized Clinical Trial. (Pubmed Central) - Oct 25, 2021
No significant difference was observed regarding the incidence of adverse events between the two groups. This study demonstrated the effectiveness and safety of intraarterial lidocaine administration using the W/O technique in controlling intra- and post-TACE pain.
- | epirubicin / Generic mfg.
Journal, PARP Biomarker: ELF4 promotes proliferation and inhibits apoptosis of human insulinoma cells by activating Akt signaling (Pubmed Central) - Oct 22, 2021
This study demonstrated the effectiveness and safety of intraarterial lidocaine administration using the W/O technique in controlling intra- and post-TACE pain. ELF4 overexpression enhances the proliferation and suppresses apoptosis of insulinomas cells by activating Akt signaling.
- || letrozole / Generic mfg., everolimus / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. (Pubmed Central) - Oct 22, 2021
P2
Everolimus plus letrozole might have positive antitumoral immunity effects. Further large randomized controlled trials are needed to confirm our findings.
- || Clinical, PK/PD data, Journal: Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). (Pubmed Central) - Oct 20, 2021
Given the interpatient variability, the identified pregnancy-induced changes in PK do not directly warrant dose adjustments for the studied drugs. Nevertheless, these results underscore the need to investigate the efficacy of chemotherapy, when administered during pregnancy.
- | epirubicin / Generic mfg.
Journal: Mitochondrial Breast Cancer Resistant Protein Sustains the Proliferation and Survival of Drug-Resistant Breast Cancer Cells by Regulating Intracellular Reactive Oxygen Species. (Pubmed Central) - Oct 20, 2021
We found that BCRP is not the major drug pump to efflux epirubicin in the resistant cells that express multiple ABC transporters...Knockdown of BCRP elevated the intracellular reactive oxygen species level and eventually promotes the cell to undergo apoptosis. This study demonstrated that BCRP exerts important onco-promoting functions in the drug-resistant breast cancer cells independent of its well-recognized drug efflux activity, which shed new light on understanding the complex functional role of ABC transporters in drug-resistant cells.
- | epirubicin / Generic mfg.
New trial: Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation (clinicaltrials.gov) - Oct 19, 2021
P=N/A, N=100, Not yet recruiting, Sponsor: Ankara Training and Research Hospital
- | Epogen (epoetin alfa) / Amgen
Journal, HEOR: Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. (Pubmed Central) - Oct 13, 2021
We showed that fatigue during adjuvant chemotherapy was mostly affected by the level of fatigue present before the start of chemotherapy. This result suggests that the level of fatigue before the start of treatment should be included as an important factor when deciding on type and toxicity of chemotherapy in early breast cancer.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Preclinical, Journal, Oncolytic virus: Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo. (Pubmed Central) - Oct 13, 2021
The combination of OVV‑Beclin1 and R‑CHOP also significantly improved tumor growth inhibition and survival in a BALB/c murine model system owing to the synergistic induction of autophagic cell death. Together, these findings suggest that OVV‑Beclin1 infection can induce significant autophagic cell death in NHL, highlighting this as a novel means of inducing tumor cell death via a mechanism that is distinct from apoptosis and necrosis.
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
New P3 trial: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma (clinicaltrials.gov) - Oct 12, 2021
P3, N=107, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov) - Oct 12, 2021
P2, N=46, Recruiting, Sponsor: Guangdong Provincial People's Hospital
Together, these findings suggest that OVV‑Beclin1 infection can induce significant autophagic cell death in NHL, highlighting this as a novel means of inducing tumor cell death via a mechanism that is distinct from apoptosis and necrosis. Not yet recruiting --> Recruiting
- ||||| Tecentriq (atezolizumab) / Roche
Enrollment closed, Surgery: GeparDouze: Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo (clinicaltrials.gov) - Oct 11, 2021
P3, N=1520, Active, not recruiting, Sponsor: NSABP Foundation Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, P2 data, Journal: A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer. (Pubmed Central) - Oct 10, 2021
Recruiting --> Active, not recruiting The combination of EN+TEC neoadjuvant chemotherapy significantly improved the ORR and OS, suggesting a benefit of adding anti-angiogenesis to standard chemotherapy in the treatment of locally advanced breast cancer.
- | epirubicin / Generic mfg.
Journal: Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. (Pubmed Central) - Oct 10, 2021
The dependence on these distinct metabolic adaptations is revealed by the increased sensitivity of doxorubicin-resistant cells and tumor xenografts to buthionine sulfoximine (BSO), a drug that interferes with glutathione synthesis, compared with epirubicin-resistant counterparts that are more sensitive to the biguanide phenformin. Overall, our work reveals that metabolic adaptations can vary with therapeutics and that these metabolic dependencies can be exploited as a targeted approach to treat chemotherapy-resistant breast cancer.
- || paclitaxel / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Biomarker, Clinical, Journal: Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. (Pubmed Central) - Oct 9, 2021
P3
The microenvironment phenotype in TNBC might have prognostic significance to patients with a high risk of recurrence. The association of the microenvironment phenotypes with the efficacy of adjuvant chemotherapy for TNBC remains to be further studied.